Lymphotoxin-Beta Receptor Blockade Reduces CXCL13 in Lacrimal Glands and Improves Corneal Integrity in the NOD Model of Sjögren's Syndrome

Roy A. Fava
Susan M. Kennedy
Sheryl G. Wood
Anne I. Bolstad

Roy A Fava;Susan M Kennedy;Sheryl G Wood;Anne I Bolstad;Jadwiga Bienkowska;Adrian Papandile;John A Kelly;Clio P Mavragani;Margaret Gatumu;Kathrine Skarstein;Jeffrey L Browning


IntroductionIn Sjögren's syndrome, keratoconjunctivitis sicca (dry eye) is associated with infiltration of lacrimal glands by leukocytes and consequent losses of tear-fluid production and the integrity of the ocular surface. We investigated the effect of blockade of the lymphotoxin-beta receptor (LTBR) pathway on lacrimal-gland pathology in the NOD mouse model of Sjögren's syndrome.MethodsMale NOD mice were treated for up to ten weeks with an antagonist, LTBR-Ig, or control mouse antibody MOPC